Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 4Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Cytarabine 9fludarabine phosphate 8fludarabine 8Radiotherapy 7Vincristine 5Cyclosporine 5Whole-Body Irradiation 4Prednisone 4Mycophenolic Acid 4Melphalan 4Filgrastim 4Etoposide 4Busulfan 4asparaginase erwinia chrysanthemi recombinant 3Tacrolimus 3Sirolimus 3Dasatinib 3Cord Blood Stem Cell Transplantation 3Bortezomib 3Asparaginase 3prednylidene 2pegaspargase 2ixazomib 2deltacortene 2blinatumomab 2Thiotepa 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Precursor Cell Lymphoblastic Leukemia-Lymphoma × CPX-351 × Clear all
NCT02269579 2018-03-14

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

Jazz Pharmaceuticals

Phase 2 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡